CX-2009

CytomX Therapeutics excels with its Probody® technology, targeting tumor microenvironments with proteolytically-activated antibodies, backed by a strong IP portfolio and experienced leadership. Despite high R&D costs and regulatory challenges, opportunities in cancer therapeutics and personalized medicine offer growth potential amidst intense competition and market volatility.

Antibody-drug conjugates (ADCs) are emerging in oncology, with dozens approved by the FDA. ADCs offer a 'bystander effect' but can increase off-target toxicity. Aditya Bardia highlighted ADCs like sacituzumab govitecan, trastuzumab deruxtecan, and datopotamab deruxtecan, which show superiority over chemotherapy in metastatic settings. Domenica Lorusso noted over 260 ADCs in cancer trials, calling them a 'rising star' in ovarian cancer. Toon Van Gorp emphasized TROP2 as a key target in cervical cancer. Challenges include understanding ADC resistance mechanisms and managing toxicities, necessitating multidisciplinary approaches.